[go: up one dir, main page]

MX2016008851A - Compuesto esteroideo para su uso en el tratamiento de encefalopatia hepatica. - Google Patents

Compuesto esteroideo para su uso en el tratamiento de encefalopatia hepatica.

Info

Publication number
MX2016008851A
MX2016008851A MX2016008851A MX2016008851A MX2016008851A MX 2016008851 A MX2016008851 A MX 2016008851A MX 2016008851 A MX2016008851 A MX 2016008851A MX 2016008851 A MX2016008851 A MX 2016008851A MX 2016008851 A MX2016008851 A MX 2016008851A
Authority
MX
Mexico
Prior art keywords
treatment
hepatic encephalopathy
steroid compound
steroid
compound
Prior art date
Application number
MX2016008851A
Other languages
English (en)
Inventor
Torbjörn Bäckström
Doverskog Magnus
MÖHLER Hanns
FELIPO Vicente
Original Assignee
Umecrine Cognition Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Cognition Ab filed Critical Umecrine Cognition Ab
Publication of MX2016008851A publication Critical patent/MX2016008851A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona el compuesto esteroideo oxima de 3a-etinil-3ß-hidroxiandrostan-17-ona, o una sal farmacéuticamente aceptable del mismo, para su uso en el tratamiento de encefalopatía hepática.
MX2016008851A 2014-01-29 2015-01-14 Compuesto esteroideo para su uso en el tratamiento de encefalopatia hepatica. MX2016008851A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1450089 2014-01-29
PCT/GB2015/050060 WO2015114308A1 (en) 2014-01-29 2015-01-14 Steroid compound for use in the treatment of hepatic encephalopathy

Publications (1)

Publication Number Publication Date
MX2016008851A true MX2016008851A (es) 2017-03-23

Family

ID=52544513

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008851A MX2016008851A (es) 2014-01-29 2015-01-14 Compuesto esteroideo para su uso en el tratamiento de encefalopatia hepatica.

Country Status (25)

Country Link
US (3) US20160339040A1 (es)
EP (1) EP3099306B1 (es)
JP (1) JP6543633B2 (es)
KR (1) KR102324667B1 (es)
CN (2) CN106163528A (es)
AU (1) AU2015212606B2 (es)
BR (1) BR112016017620A2 (es)
CA (1) CA2935015C (es)
CY (1) CY1121464T1 (es)
DK (1) DK3099306T3 (es)
ES (1) ES2714563T3 (es)
HR (1) HRP20190251T1 (es)
HU (1) HUE042242T2 (es)
IL (1) IL246496B (es)
LT (1) LT3099306T (es)
ME (1) ME03351B (es)
MX (1) MX2016008851A (es)
PL (1) PL3099306T3 (es)
PT (1) PT3099306T (es)
RS (1) RS58375B1 (es)
RU (1) RU2684616C2 (es)
SI (1) SI3099306T1 (es)
SM (1) SMT201900133T1 (es)
TR (1) TR201901687T4 (es)
WO (1) WO2015114308A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3099306T3 (pl) 2014-01-29 2019-06-28 Umecrine Cognition Ab Steroidowy związek do zastosowania do leczenia encefalopatii wątrobowej
AR103384A1 (es) 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
JP7203438B2 (ja) 2017-09-12 2023-01-13 イーティーエイチ・チューリッヒ 体液中アンモニア定量用の膜貫通ｐＨ勾配ポリマーソーム
IL274893B2 (en) 2017-11-27 2024-08-01 Umecrine Cognition Ab Pharmaceutical formulation of 3 alpha-ethynyl-3 beta-hydroxyandrostan-17-one oxime
EP4079307A1 (en) 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use
US20230134958A1 (en) * 2021-10-29 2023-05-04 Umecrine Cognition Ab New medical treatment
EP4389129A1 (en) * 2022-12-22 2024-06-26 Umecrine Cognition AB 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia
WO2025252725A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone
WO2025252724A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2713061A (en) 1951-04-06 1955-07-12 Schering Ag 3-methyl androstanes
FR1463755A (fr) 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3173932A (en) 1962-11-02 1965-03-16 American Cyanamid Co 15-substituted estra-1, 3, 5(10)-trienes
FR2685332A1 (fr) 1991-12-20 1993-06-25 Roussel Uclaf Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments.
JP4008024B2 (ja) 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Ｇａｂａａレセプター複合体と相互作用させるための化合物
CA2321728C (en) 1998-03-11 2008-12-09 Torbjorn Backstrom Epiallopregnanolone in the treatment of cns disorders
US6593321B2 (en) 2001-06-11 2003-07-15 Southwest Foundation For Biomedical Research 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
SE0104423D0 (sv) * 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
PL1824563T3 (pl) 2004-11-26 2010-07-30 Ucl Business Plc Kompozycje zawierające ornitynę i fenylooctan lub fenylomaślan do leczenia encefalopatii wątrobowej
WO2007103162A2 (en) * 2006-03-01 2007-09-13 Samaritan Pharmaceuticals, Inc. Structure based drug design of steroidogenesis inhibitors
HUE036410T2 (hu) * 2006-11-21 2018-07-30 Asarina Pharma Ab Pregnán és androsztán szteroidok alkalmazása CNS rendellenességek kezelésére szolgáló gyógyszerkészítmény elõállítására
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
EP4342465A3 (en) * 2008-10-02 2024-06-12 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
MX2011013129A (es) 2009-06-08 2012-03-14 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
US20150094278A1 (en) 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy
PL3099306T3 (pl) 2014-01-29 2019-06-28 Umecrine Cognition Ab Steroidowy związek do zastosowania do leczenia encefalopatii wątrobowej

Also Published As

Publication number Publication date
PT3099306T (pt) 2019-03-21
KR102324667B1 (ko) 2021-11-10
CN113185566A (zh) 2021-07-30
ME03351B (me) 2019-10-20
US20180015103A1 (en) 2018-01-18
TR201901687T4 (tr) 2019-02-21
JP2017507113A (ja) 2017-03-16
PL3099306T3 (pl) 2019-06-28
SI3099306T1 (sl) 2019-03-29
US10342804B2 (en) 2019-07-09
US20160339040A1 (en) 2016-11-24
BR112016017620A2 (pt) 2017-08-08
IL246496A0 (en) 2016-08-31
CY1121464T1 (el) 2020-05-29
EP3099306B1 (en) 2018-12-12
US20170056416A1 (en) 2017-03-02
RS58375B1 (sr) 2019-03-29
HRP20190251T1 (hr) 2019-04-05
WO2015114308A1 (en) 2015-08-06
AU2015212606A1 (en) 2016-07-14
DK3099306T3 (en) 2019-03-18
RU2016127558A (ru) 2018-03-05
WO2015114308A8 (en) 2016-07-21
NZ721622A (en) 2020-11-27
KR20160105922A (ko) 2016-09-07
LT3099306T (lt) 2019-03-12
IL246496B (en) 2019-09-26
RU2016127558A3 (es) 2018-09-27
CN106163528A (zh) 2016-11-23
US9801894B2 (en) 2017-10-31
JP6543633B2 (ja) 2019-07-10
SMT201900133T1 (it) 2019-05-10
RU2684616C2 (ru) 2019-04-10
ES2714563T3 (es) 2019-05-29
EP3099306A1 (en) 2016-12-07
CA2935015C (en) 2022-05-31
CA2935015A1 (en) 2015-08-06
HUE042242T2 (hu) 2019-06-28
AU2015212606B2 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
IL292461A (en) Neuroactive steroids, preparations and their uses
IL285703A (en) Neuroactive steroids, preparations and their uses
MX2016008851A (es) Compuesto esteroideo para su uso en el tratamiento de encefalopatia hepatica.
IL261658A (en) Neuroactive steroids, preparations and their uses
EP3192518A4 (en) Anti-inflammatory agent
PL3221333T3 (pl) Steroidy, 6.alfa-alkilo-3,7-diony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
GB2557319B (en) Toilet for use while squatting, components thereof, and processes for its manufacture
SG10202108899XA (en) Anti-inflammatory agent
EP3676957A4 (en) CLASS C OSCILLATOR
EP3204120A4 (en) Methods and compositions for increasing the potency of antifungal agents
KR101881842B1 (ko) 남성용 비데
HK40009965A (en) Dose determination for immunotherapeutic agents
AU2017901690A0 (en) Improvements for respiratory masks
CA3279948A1 (en) Neuroactive steroids, compositions, and uses thereof
IN2014MU00599A (es)
GB201504709D0 (en) System for evacuating toilet odors
GB201502746D0 (en) System for evacuating toilet odors
GB201502747D0 (en) System for evacuating toilet odors
GB201506916D0 (en) System for evacuating toilet odours

Legal Events

Date Code Title Description
FG Grant or registration